In closing, our study offered evidence demonstrating that KIF11 is highly expressed in CRC, correlating with certain clinical parameters, and that knockdown of KIF11 markedly impaired tumor growth and sensitized CRC cells to oxaliplatin treatment via activation of p53 signaling and deactivation of GSK3β signaling. Here, GSK3B is linked to colorectal carcinoma.